The application of quantum computing to drug discovery can enable an enhanced level of accuracy in estimating molecular properties and conducting chemical simulations. However, there is a considerable distance between real drug-like molecular data and their accessibility for quantum computational analysis. Here, we present an automated, scalable framework that can bridge this gap by extracting drug-like molecules from publicly available biomedical databases, optimizing their molecular geometries, and producing quantum-ready Hamiltonians using widely accepted techniques in quantum chemistry. This method uses the ChEMBL v28 database to retrieve molecules with zero Rule-of-5 violations, maintaining pharmaceutical applicability. These molecules are then prepared using RDKit to convert SMILES notations into chemically valid 3D geometries, enabling force-field-based optimization and downstream quantum analysis. Once these geometries are ready, we use the quantum chemistry module of PennyLane to prepare an electronic Hamiltonian for Variational Quantum Eigensolver (VQE) simulations. This work describes an automated workflow that converts classical molecular information into quantum-ready formats, developed for advanced simulations on noisy quantum simulators and nearterm quantum hardware. Although classical methods remain essential due to their speed and scalability, our study demonstrates that quantum methods can offer competitive accuracy in estimating molecular energies-an important factor in evaluating drug behavior. In conclusion, this paper represents a data-driven link between current chemical databases and next-generation quantum techniques, while also offering an initial roadmap for quantum-accelerated molecular design in the drug discovery arena.
The application of quantum computing to drug discovery can enable an enhanced level of accuracy in estimating molecular properties and conducting chemical simulations. However, there is a considerable distance between real drug-like molecular data and their accessibility for quantum computational analysis. Here, we present an automated, scalable framework that can bridge this gap by extracting drug-like molecules from publicly available biomedical databases, optimizing their molecular geometries, and producing quantum-ready Hamiltonians using widely accepted techniques in quantum chemistry. This method uses the ChEMBL v28 database to retrieve molecules with zero Rule-of-5 violations, maintaining pharmaceutical applicability. These molecules are then prepared using RDKit to convert SMILES notations into chemically valid 3D geometries, enabling force-field-based optimization and downstream quantum analysis. Once these geometries are ready, we use the quantum chemistry module of PennyLane to prepare an electronic Hamiltonian for Variational Quantum Eigensolver (VQE) simulations. This work describes an automated workflow that converts classical molecular information into quantum-ready formats, developed for advanced simulations on noisy quantum simulators and nearterm quantum hardware. Although classical methods remain essential due to their speed and scalability, our study demonstrates that quantum methods can offer competitive accuracy in estimating molecular energies-an important factor in evaluating drug behavior. In conclusion, this paper represents a data-driven link between current chemical databases and next-generation quantum techniques, while also offering an initial roadmap for quantum-accelerated molecular design in the drug discovery arena.
Over the past few years, artificial intelligence (AI) and quantum computing have emerged as groundbreaking technologies in the field of drug discovery. Techniques like AI-driven molecular design, quantum-enhanced simulations, and hybrid approaches have made significant strides in tackling the complexity of drug-target interactions. However, current models still face key challenges, such as the limited scalability of quantum systems, the difficulty of generalizing AI models due to insufficient data quality, and the inefficiencies in merging quantum and classical methods. To overcome these obstacles, this paper introduces a new hybrid quantum-AI workflow. By combining the precision of quantum computing for molecular simulations with the predictive power of AI, this approach aims to improve accuracy, scalability, and efficiency in drug discovery, paving the way for future breakthroughs in the field.
The integration of quantum computing and artificial intelligence (AI), collectively termed Quantum AI, is revolutionizing the pharmaceutical industry by reshaping the paradigms of drug discovery and development. Traditional approaches to drug design are often limited by high costs, extensive timelines, and the computational intractability of simulating complex molecular interactions. Quantum computing offers exponential processing power, enabling the accurate modeling of quantum-level chemical phenomena that classical computers struggle to handle. Concurrently, AI contributes by enhancing data interpretation, prediction of molecular behaviors, and pattern recognition across large biological datasets. Together, Quantum AI enables faster identification of drug candidates, improved simulation of drug-target interactions, and early prediction of pharmacokinetics and toxicity. Key quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and quantum-enhanced machine learning, have demonstrated potential to outperform conventional methods in quantum chemical calculations. Moreover, this synergy facilitates personalized medicine by integrating patient-specific data to optimize therapeutic outcomes. Despite current challenges related to hardware scalability, algorithm optimization, and ethical integration, the future trajectory of Quantum AI is poised to redefine pharmaceutical innovation. This review underscores the transformative capabilities of Quantum AI and its potential to usher in a new era of efficient, cost-effective, and precision-driven drug development.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
Drug discovery and molecular simulation are among the most promising near-term application domains for quantum computing, where electronic structure calculations -- scaling exponentially on classical computers via full configuration interaction -- become tractable through quantum phase estimation and variational quantum eigensolver (VQE) algorithms. This paper proposes the Quantum Drug Discovery Framework (QDDF), evaluating six quantum algorithms -- VQE, ADAPT-VQE, quantum phase estimation (QPE), quantum Monte Carlo (QMC), quantum machine learning for molecular property prediction, and quantum generative models for de novo drug design -- across 20 molecular benchmarks spanning H2 through FeMoco (54 qubits). Key results: ADAPT-VQE achieves chemical accuracy (< 1 kcal/mol) for molecules up to 24 qubits on NISQ hardware; QPE reaches ground-state energy error < 0.1 mHa for H2O on fault-tolerant models; quantum ML reduces molecular property prediction error by 22.4% versus classical graph neural networks. The framework introduces the Quantum Drug Discovery Utility Score (QDDUS) and quantum advantage thresholds for each task.
INTRODUCTION: Quantum computing represents a transformative advancement in computational science, with applications in drug discovery, molecular interaction simulation, drug-target binding optimization, and the analysis of complex biological data at unprecedented speeds and accuracy. Quantum computing emerges as a powerful tool to accelerate the development of new therapeutics, drug design, and the simulation of complex chemical interactions, including personalized medicine strategies. The objective of this study is to explore the potential of quantum computing in drug discovery and development, highlighting its ability to reduce time and costs while accelerating the identification of promising drug candidates. METHODS: Quantum computing algorithms, such as Grover's algorithm and the Variational Quantum Eigensolver (VQE), are utilized to simulate molecular interactions of drugs and optimize drug design. In case studies, such as IBM's use of VQE for molecular simulations, these technologies demonstrate their effectiveness. RESULTS: Quantum computing has shown promise in addressing several technological barriers, such as lengthy development timelines and high costs. Additionally, demonstrated success in molecular simulations and solving challenges during the drug development process. However, challenges related to error rates, qubit coherence, and regulatory compliance remain. DISCUSSION: This study examines the applications of quantum computing in drug discovery, highlighting key techniques such as quantum simulation, quantum machine learning, and optimization algorithms. Quantum computing is crucial for interdisciplinary collaboration among quantum physicists, computational chemists, biologists, and pharmaceutical professionals, as it is essential to overcoming these obstacles and realizing the full potential of quantum technologies in medicine. CONCLUSION: Quantum computing holds great potential in drug discovery and development, offering accelerated, more accurate, and lower-cost research avenues, particularly in complex areas such as protein folding prediction and personalized medicine. This new paradigm has tremendous potential for guiding the future of pharmaceutical development and patient-focused medicine.
Quantum chemistry plays a crucial role in advancing fundamental understanding of chemical processes and driving innovation in energy, medicine, and materials science. Recent progress in quantum computing has opened new possibilities for molecular simulations that are beyond the practical limits of classical approaches. Academic studies have demonstrated hybrid Density Functional Theory (DFT) and Variational Quantum Eigensolver (VQE) benchmarks on small transition-metal systems, such as iron porphyrin and heme analogues, using current noisy intermediate-scale quantum (NISQ) hardware. Although full-scale simulations of complex biological systems such as the complete Cytochrome P450 (CYP450) active site remain a long-term goal due to limitations in qubit numbers, coherence times, and error correction, the underlying methodologies are now well established. At present, quantum chemistry applications in drug discovery remain largely experimental, and widespread practical medical impact is expected to require further technological advances over the next 5–10 years. Nevertheless, quantum software and algorithm development for chemical applications is progressing rapidly. This perspective summarizes recent advances in quantum computing algorithms, hardware, and software relevant to chemistry, and critically discusses the remaining challenges and opportunities for applying quantum computing to chemical problems, with particular emphasis on drug discovery and development.